Later-Line Combination Therapies Used as Treatment in Multiple Myeloma

Samer A. Al’Hadidi, MD, discusses the importance of personalized medicine in patients with multiple myeloma.

Samer A. Al'Hadidi, MD, MS, discusses the response and survival of 2 quadruplet therapy trials for patients with transplant-ineligible multiple myeloma.

During a Case-Based Roundtable® event, Andrzej Jakubowiak, MD, PhD, surveyed how newer regimens influence a patient case of a 79-year-old with newly diagnosed multiple myeloma in the second article of a 2-part series.

During a Case-Based Roundtable® event, Andrzej Jakubowiak, MD, PhD, discussed 2 recent trials in multiple myeloma for isatuximab combination treatment in the first article of a 2-part series.

During a Case-Based Roundtable® event, Andrew Yee, MD, discussed myeloma treatment strategies for different age groups, focusing on personalized regimens and the pros and cons of CAR T-cell therapy and bispecific antibodies in the second article of a 2-part series.

During a Case-Based Roundtable® event, Andrew Yee, MD, discussed the use of carfilzomib-based regimens compared with other options for patients with multiple myeloma, including those refractory to lenalidomide in the first article of a 2-part series.

During a Case-Based Roundtable® event, Ariel Grajales-Cruz, MD, discussed the long-term results of the phase 3 IKEMA study that build the rationale for use of the triplet therapy isatuximab, carfilzomib, and dexamethasone, in patients with relapsed/refractory multiple myeloma in the second article of a 2-part series.

During a Case-Based Roundtable® event, Ariel Grajales-Cruz, MD, discussed how the use of the isatuximab, carfilzomib, and dexamethasone triplet regimen led to deeper responses in patients with relapsed/refractory multiple myeloma.

During a Case-Based Roundtable® event, Cristiana Costa Chase, MD, discussed the recommended regimens and trials supporting therapies following lenalidomide-refractory relapse of multiple myeloma in the second article of a 2-part series.

During a Case-Based Roundtable® event, Cristiana Costa Chase, MD, discussed the IKEMA trial of isatuximab, carfilzomib, and dexamethasone in patients with relapsed/refractory multiple myeloma in the first article of a 2-part series

In the second article of a 2-part series, Douglas Sborov, MD, discusses the toxicities seen with isatuximab and how this therapy can impact patients in rural areas relying on community center treatment.

In the first article of a 2-part series, Douglas Sborov, MD, discusses how the efficacy results of the IKEMA trial not only show isatuximab, carfilzomib, and dexamethasone as a viable treatment option for patients with multiple myeloma, but as further proof triplet therapy is superior to doublet therapy in this patient population.

In the second article of a 2-part series, Joshua Richter, MD, discusses how the isatuximab, carfilzomib, and dexamethasone regimen fits into the landscape of treatment for patients with early relapsed multiple myeloma.

In the first article of a 2-part series, Joshua Richter, MD, discussed how the triplet therapy of isatuximab, carfilzomib and dexamethasone, has impacted treatment considerations for patients with high-risk multiple myeloma.

Joshua Richter, MD, discusses the available combination therapies for patients with early relapsed/refractory multiple myeloma using anti-CD38 monoclonal antibodies.

In the second article of this 2-part series, Douglas Sborov, MD, discusses the relevant data that shows the benefit of giving patients with relapsed/refractory multiple myeloma isatuximab as part of a triplet therapy.

Douglas Sborov, MD, MS, discusses and compares the many triplet therapies for patients who show disease progression after several lines of therapy in this first article of a 2 part series.

During a Targeted Oncology™ Case-Based Roundtable™ event, Suzanne Lentzsch, MD, PhD, discussed with participants their views on the IKEMA trial of isatuximab, carfilzomib, and dexamethasone in patients with multiple myeloma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Suzanne Lentzsch, MD, PhD, discussed with participants their choice of combination therapy after disease relapse of multiple myeloma.